Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe something else may be announced today at the conference at 3pm.
imho
all that means is investors like myself think this is worth more than 4.28 I believe 6-7 is more like it. I think we will see a bidding war soon. the deal is not signed yet, just on the table.
go cvrs
News: $CVRS Corindus Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Corindus Vascular Robotics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - CVRS
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Corindus Vascular Robotics, Inc. (NYSE AMERICAN: CVRS) to Siemens Healthineers AG for $4.28 per share is fair to Corindus shareholders. On behalf of Corindus...
Find out more Corindus Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Corindus Vascular Robotics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - CVRS
I usually am a long player. It depends on what your looking for. A portfolio keeper , dividends or the first bump . I personally would set tight and keep close DD on everything.
News: $CVRS Corindus Reports Second Quarter 2019 Results
Corindus announced today a definitive agreement to be acquired by Siemens Healthineers for approximately $1.1 billion, or $4.28 per share, in an all-cash transaction Second quarter revenue of $4.6 million reflects increasing adoption and utilization in U.S. and abroad Corindus ...
Read the whole news Corindus Reports Second Quarter 2019 Results
News: $CVRS Corindus Vascular Robotics Announces Definitive Agreement to Be Acquired by Siemens Healthineers
-- Corindus Stockholders to Receive $4.28 Per Share -- -- All-Cash Transaction Valued at Approximately $1.1 Billion -- Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has entered into a definitive...
Read the whole news Corindus Vascular Robotics Announces Definitive Agreement to Be Acquired by Siemens Healthineers
ok so what now? do you sell at 4.28 or wait and see if a bidding war starts. guys on stock twits are saying Philips and Medtronic are also interested, and that this is just the beginning of a bidding war.
any thoughts
that explains the 75% increase in price. and to think almost bought more yesterday
* * $CVRS Video Chart 08-06-2019 * *
Link to Video - click here to watch the technical chart video
* * $CVRS Video Chart 08-05-2019 * *
Link to Video - click here to watch the technical chart video
News: $CVRS Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities
One of the nation’s largest hospital networks adopts vascular robotic technology in multiple hospital locations to treat patients in need of cardiovascular care Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), ...
Read the whole news Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities
Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities
https://www.businesswire.com/news/home/20190718005211/en/
Surgical Robotics Market to Reach a Market Size of $98 Billion by 2024 - KBV Research
https://www.prnewswire.com/news-releases/surgical-robotics-market-to-reach-a-market-size-of-98-billion-by-2024-kbv-research-824074651.html
New Robotic Vascular Surgery Technology Being Used At Tampa Bay Area Hospital
https://news.wjct.org/post/new-robotic-vascular-surgery-technology-being-used-tampa-bay-area-hospital
AWESOME NEWS, FDA NEXT THEN WE GO TO 10. I ALSO SAW AN ARTICLE ABOUT CORPATH IN A TAMPA BAY HOSPITAL. GO BABY GO
Corindus Announces Regulatory Approval of CorPath GRX for Neurovascular !
https://www.businesswire.com/news/home/20190717005240/en/Corindus-Announces-Regulatory-Approval-CorPath-GRX-Neurovascular/
Directors James R Tobin & Douglas L Braunstein picked up more shares July 8th.
http://www.conferencecalltranscripts.org/4/summary2/?id=6438558
http://www.conferencecalltranscripts.org/4/summary/?id=6438557
Nice more insiders buying forms filed tonight. The boom is coming. NEXT ISRG
stick around I think things are about to get a lot more fun.
THANKS , I need to get myself educated more in this sector. In any event having this has been fun.
I work in the medical device industry. Now this is only in my opinion, but I feel this company would be a good fit for a larger medical device company that wants to get into robotic surgery. Companies like MEDTRONIC or BOSTON SCIENTIFIC would be a good example.
IMHO
When I bought this i thought it was a buy out stock / merger/ but now wondering who would be the potential partner. I'm not knowledgeable enough in this sector to get a handle…any thoughts
I believe we will blow out earnings this quarter and be cash flow positive in the 3rd quarter. . I still believe we could see 10 by end of year. Sooner if or when a partner or buyout. Is announced. Go cvrs. Way undervalued here
IMHO
* * $CVRS Video Chart 07-08-2019 * *
Link to Video - click here to watch the technical chart video
too bad you're a donky!!
I'm thinking this could be a multi month runner into January once ATHs are reached.
Green with above average volume Major breakout coming. This stock is way undervalued. Next Isrg
Probably caused by the Russell rebalancing
Dam. Almost a 8 million share trade at end of day. This stock will rocket soon. I'm thinking profitable in q3. The. Skies the limit after that. next ISRG in the making
IMHO
I'm looking to add a little more on this dip, imo this wants to go to new highs..
Get ready for a very down week!!
CVRS about to go crazy!!! Massive technical breakout!!
CVRS get ready for an exciting week!!
This reminds me of ISRG, rare opportunity..small cup n handle on the daily chart and double top breakout.
Getting interesting here. New 52 week high. Huge buy after hours on Friday. I believe a partner or buyout is coming. Insiders buying as well. GO CVRS.
CVRS long and strong...link back...time to make some noise!!
Followers
|
21
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
431
|
Created
|
06/06/12
|
Type
|
Free
|
Moderators |
Corindus Vascular Robotics, Inc.(CVRS) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The Company?s FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through of improper stent placement with manual PCI procedures.
Dr. Vijay Lyer's Story
Interventional cardiologist, Dr. Vijay Iyer, has spent his career providing lifesaving care to his patients, all while wearing heavy lead apparel to protect himself from the harmful effects of radiation exposure required for his procedures. Unfortunately, the lead apparel required during percutaneous coronary interventions, or PCI, and other procedures in the cath lab has led to serious spinal injuries for Dr. Iyer. After four back surgeries, Dr. Iyer was faced with the grim reality that one more surgery may end his career in the cath lab. The orthopedic injuries he faced are unfortunately very common among interventional cardiologists and other cath lab personnel with 60% of interventionalists with more than 20 years in the lab experiencing spinal issues.
Dr. Iyer was committed to finding a solution that would allow him to continue in interventional cardiology without the need for heavy lead apparel. This video highlights how Dr. Iyer is avoiding further injury by routinely utilizing CorPath, the first robotic system cleared for PCI, which enables him to provide a high level of care for his patients from the safety of a radiation-protected interventional cockpit.
http://www.corindus.com/news-events/press-releases/september-16-2015
How it works
http://www.corindus.com/corpath-grx/how-it-works
Market Value1 | $286,233,809 | a/o Jun 13, 2017 | |
Authorized Shares | 250,000,000 | a/o Dec 31, 2014 | |
Outstanding Shares | 187,080,921 | a/o May 08, 2017 |
Common Stock, $0.0001 Par Value | Additional Paid-in | Accumulated | ||||||||||||||||||
Shares | Amount | Capital | Deficit | Total | ||||||||||||||||
Balance at December 31, 2016 | 119,025,221 | $ | 12 | $ | 150,776 | $ | (146,718 | ) | $ | 4,070 | ||||||||||
Stock-based compensation expense | — | — | 792 | — | 792 | |||||||||||||||
Issuance of common stock in connection with private placement of common stock, net of issuance costs of $415 | 68,055,700 | 7 | 44,604 | — | 44,611 | |||||||||||||||
Net loss | — | — | — | (9,885 | ) | (9,885 | ) | |||||||||||||
Balance at March 31, 2017 | 187,080,921 | $ | 19 | $ | 196,172 | $ | (156,603 | ) | $ | 39,588 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |